Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as a once-weekly injection and a ...
No. 13 / 2026 New data from Phase 2 ZUPREME-1 trial at the American Diabetes Association 2026 Scientific Sessions further support ...
Weekly subcutaneous injections of the novel B-cell inhibitor obexelimab significantly reduces disease flares and lowers toxic ...
TG Therapeutics reported phase 1 data showing its subcutaneous Briumvi formulation delivered measurable drug exposure and ...
TG Therapeutics, Inc.'s Phase 1 results of subcutaneous Briumvi are a major de-risking event. Click here to read more about ...
The number of patients with Parkinson's disease (PD) who initiated device-aided therapies (DAT) increased by 41.8% between ...
Shares of TG Therapeutics rose after the company reported positive data for new subcutaneous formulation of a multiple sclerosis treatment. The stock climbed 12%, to $41.21, Wednesday afternoon and is ...
Enrollment in a randomized Phase 2 trial for Systemic Lupus Erythematosus is completed. Zenas expects to report topline ...
GIP infusion as add-on to placebo or semaglutide did not improve glycaemic control in individuals with type 2 diabetes at the prespecified target of 1·50 mmol/L. Due to dropouts, we cannot draw firm ...
Roche launched Tecentriq SC in India, reducing lung cancer immunotherapy delivery time from hours to just seven minutes.
(MENAFN- EIN Presswire) EINPresswire/ -- "Subcutaneous Drug Delivery Devices market to surpass $50 billion in 2030. In comparison, the Drug-Delivery Technology market, which is considered as its ...
AstraZeneca’s Saphnelo has been approved in the US for self‑administration as a once‑weekly autoinjector, the Saphnelo Pen, for adults with systemic lupus erythematosus receiving standard therapy. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results